Literature DB >> 18482836

IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.

George M Buckley1, Thomas A Ceska, Joanne L Fraser, Lewis Gowers, Colin R Groom, Alicia Perez Higueruelo, Kerry Jenkins, Stephen R Mack, Trevor Morgan, David M Parry, William R Pitt, Oliver Rausch, Marianna D Richard, Verity Sabin.   

Abstract

A potent IRAK-4 inhibitor was identified through routine project cross screening. The binding mode was inferred using a combination of in silico docking into an IRAK-4 homology model, surrogate crystal structure analysis and chemical analogue SAR.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18482836     DOI： 10.1016/j.bmcl.2008.04.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  12 in total

1.  Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.

Authors:  Jongwon Lim; Michael D Altman; James Baker; Jason D Brubaker; Hongmin Chen; Yiping Chen; Thierry Fischmann; Craig Gibeau; Melanie A Kleinschek; Erica Leccese; Charles Lesburg; John K F Maclean; Lily Y Moy; Erin F Mulrooney; Jeremy Presland; Larissa Rakhilina; Graham F Smith; Dietrich Steinhuebel; Ruojing Yang
Journal:  ACS Med Chem Lett       Date:  2015-04-20       Impact factor: 4.345

2.  Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Authors:  Bernard Barlaam; Judith Anderton; Peter Ballard; Robert H Bradbury; Laurent F A Hennequin; D Mark Hickinson; Jason G Kettle; George Kirk; Teresa Klinowska; Christine Lambert-van der Brempt; Cath Trigwell; John Vincent; Donald Ogilvie
Journal:  ACS Med Chem Lett       Date:  2013-05-31       Impact factor: 4.345

3.  A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase.

Authors:  Scott A Scarneo; Philip F Hughes; Kelly W Yang; David A Carlson; Deepak Gurbani; Kenneth D Westover; Timothy A J Haystead
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

4.  Group B Streptococci Induce Proinflammatory Responses via a Protein Kinase D1-Dependent Pathway.

Authors:  Kirtikumar Upadhyay; Jeoung-Eun Park; Tae Won Yoon; Priyanka Halder; Young-In Kim; Victoria Metcalfe; Ajay J Talati; B Keith English; Ae-Kyung Yi
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

Review 5.  Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases.

Authors:  Sushmita Jha; Jenny P-Y Ting
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

6.  Outcome of a workshop on applications of protein models in biomedical research.

Authors:  Torsten Schwede; Andrej Sali; Barry Honig; Michael Levitt; Helen M Berman; David Jones; Steven E Brenner; Stephen K Burley; Rhiju Das; Nikolay V Dokholyan; Roland L Dunbrack; Krzysztof Fidelis; Andras Fiser; Adam Godzik; Yuanpeng Janet Huang; Christine Humblet; Matthew P Jacobson; Andrzej Joachimiak; Stanley R Krystek; Tanja Kortemme; Andriy Kryshtafovych; Gaetano T Montelione; John Moult; Diana Murray; Roberto Sanchez; Tobin R Sosnick; Daron M Standley; Terry Stouch; Sandor Vajda; Max Vasquez; John D Westbrook; Ian A Wilson
Journal:  Structure       Date:  2009-02-13       Impact factor: 5.006

7.  Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-a]pyridine derivatives.

Authors:  Brendan Frett; Nicholas McConnell; Anupreet Kharbanda; Gunaganti Naresh; Benjamin Rounseville; Christina Warner; John Chang; Natalie Debolske; Hong-Yu Li
Journal:  Tetrahedron       Date:  2018-07-17       Impact factor: 2.457

Review 8.  Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.

Authors:  Swati Bhattacharyya; John Varga
Journal:  Immunol Lett       Date:  2017-09-28       Impact factor: 3.685

9.  Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.

Authors:  Sirish K Ippagunta; Julie A Pollock; Naina Sharma; Wenwei Lin; Taosheng Chen; Kazuki Tawaratsumida; Anthony A High; Jaeki Min; Yizhe Chen; R Kiplin Guy; Vanessa Redecke; John A Katzenellenbogen; Hans Häcker
Journal:  Sci Signal       Date:  2018-08-14       Impact factor: 8.192

Review 10.  IRAK-4 inhibitors for inflammation.

Authors:  Zhulun Wang; Holger Wesche; Tracey Stevens; Nigel Walker; Wen-Chen Yeh
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.